The company’s financial buffer remains formidable: €16.76 billion in cash and marketable securities. Yet even as BioNTech pours money into its cancer programs, it is simultaneously slimming down its ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...

BioNTech rolled out an extensive clinical dataset at this year’s ASCO conference, yet its shares continue to trade well below their highs — a disconnect that has frustrated bulls and left the company ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds An update from ...

German biotech BioNTech and and US pharma major Bristol Myers Squibb announced interim Phase II data from the global Phase II ...

BERLIN (Reuters) -BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German ...

Large Pipeline The first-quarter figures were sobering. BioNTech generated revenue of just EUR 118.1 million, a decline of ...

View BioNTech SE Sponsored ADR BNTX stock quote prices, financial information, real-time forecasts, and company news from CNN.